Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kartos Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women \> 18 years old
Pathologically-documented, definitively-diagnosed AML that is relapsed or refractory to standard treatment, for which no standard therapy is available or the subject refuses standard therapy
Ability to take oral medications and willing to record daily adherance to investigational product
Adequate hematological, renal, hepatic, and coagulation laboratory assessments
You may not be if
Active infection requiring intravenous (IV) antibiotics
Prior participation in an investigational study (procedure or device) within 21 days of study day 1
Major surgery within 28 days of study day 1
Anti-tumor therapy within 14 days of study day 1
Clareo Health | A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
